Stock comparison
Galapagos N.V.
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GLPG
Galapagos N.V.
Market cap
$1.81B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GLPG | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 41D | 75B | IDXX |
| Benjamin Graham | 28F | 80A | IDXX |
| Philip Fisher | 56C | 75B | IDXX |
| Peter Lynch | 76B | 71B | GLPG |
| Joel Greenblatt | 39D | 83C | IDXX |
| Charlie Munger | 46D | 87A | IDXX |
| Terry Smith | 46D | 84A | IDXX |
Side-by-side metrics
| Metric | GLPG | IDXX |
|---|---|---|
| Market cap | $1.81B | $44.12B |
| P/E (TTM) | 3.1x | 39.0x |
| EV/EBIT | 2.9x | 31.6x |
| ROIC (TTM) | 17.67% | 40.66% |
| Gross margin | 98.01% | 62.05% |
| Net margin | 46.83% | 24.63% |
| Revenue CAGR 5y | 23.07% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.0x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GLPG leads on
- Debt / Equity0.0xvs 0.7x+100%
- P/E (TTM)3.1xvs 39.0x+92%
- EV/EBIT2.9xvs 31.6x+91%
- Revenue CAGR 5y23.07%vs 7.56%+67%
IDXX leads on
- Market cap$44.12Bvs $1.81B+96%
- ROIC (TTM)40.66%vs 17.67%+57%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.